Japan Approves Pharming's Joenja for APDS, First Treatment for Children Aged 4-11 Globally
summarizeSummary
Pharming Group has received regulatory approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Joenja® (leniolisib) to treat Activated PI3K delta syndrome (APDS) in patients aged 4 years and older. This is a highly significant development as Joenja is now the first approved treatment for APDS in Japan and notably, the first globally approved treatment for children aged 4 to 11 with the rare disease. This approval expands the market opportunity for Joenja, which is already available in the US and UK for older patients, and is expected to drive future revenue growth, building on the company's recently reported strong financial performance for 2025. Investors will now focus on the upcoming agreement with the MHLW on the National Health Insurance drug price and the subsequent product launch in Japan.
At the time of this announcement, PHAR was trading at $16.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.50 to $21.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.